AZ-LIMELIGHT-NETWORKS
23.6.2020 13:02:07 CEST | Business Wire | Press release
The COVID-19 pandemic is impacting lives across the globe, forcing people to change how they work, learn, access information, connect with one another and their entertainment options. Streaming is at the forefront of this new normal with global consumers now engaging with online video for an average of four hours and three minutes every day. That is according to a new global “How Video is Changing the World” report from Limelight Networks , Inc., (Nasdaq: LLNW), which exposes the new ways online video supports our daily activities during and after the pandemic.
As people quarantine in their homes, online video is enabling new forms of interactive entertainment to pass the time. With traditional sports leagues on hold, nearly one third (31 percent) of global consumers have had their first esports experience during the pandemic. With other live events cancelled, almost half (44 percent) of global consumers attended their first virtual concert. Exercising is also going virtual as athletic facilities remain closed. In fact, 31 percent have participated in an online fitness class and another 24 percent plan to in the next six months.
Additional insights from the report include:
- Online video fills the void of in-person social interactions. Globally, nine in ten (89 percent) people now use video chat to feel more connected, up from 61 percent prior to COVID-19.
- Consumers are using online video to access critical information. Most people (70 percent) have used online video to stay informed by watching live stream speeches and press conferences during the pandemic – 44 percent live streamed on news sites and 26 percent live streamed on social media. Even Baby Boomers (63 percent) tune into live streamed news and information online.
- Remote work and professional development rely on online video. As the pandemic has forced consumers to work remotely, 79 percent of people agree that online video equips them to maintain daily activities. One third (33 percent) of global consumers are working from home for the first time and say online video helps them stay connected to colleagues (24 percent) and work more efficiently (36 percent). More than half (58 percent) have or plan to use online video for professional development or to learn a new skill. Most people (83 percent) believe video-based learning will continue in the post-COVID world.
- The pandemic has sparked a rapid increase in telehealth across the globe. More than one fifth (22 percent) of people have recently met with their doctor virtually. This trend is expected to last beyond the pandemic with another quarter (27 percent) of global respondents planning to hold telehealth appointments in the next six months. Telehealth usage is highest for India where 81 percent of consumers have met or plan to meet with their doctor virtually.
“The pandemic has pushed the bounds of online video. Applications such as remote collaboration, e-learning and telehealth, have been widely available for some time now; but today, they’re essential to continuing life in quarantine,” said Mike Milligan, senior director of product and solution marketing at Limelight Networks. “Many people turned to online video to connect with others and maintain daily activities during the pandemic, but it won't stop once quarantine is over. Our report emphasizes that online video will remain an important part of our lives in the new normal.”
The “How Video is Changing the World” report is based on responses from 5,000 consumers ages 18 and older in France, Germany, India, Italy, Japan, Scandinavia, Singapore, South Korea, the United Kingdom, and the United States who watch one hour or more of online video each day. The full report is available here .
About Limelight Networks
Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com
, follow us on Twitter
, Facebook
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom